ORDER（OrderlyNetwork） fluctuated by 44.1% in 24 hours: Surge in trading volume driven by perpDEX upgrade
Bitget Pulse2026/04/08 12:51Volatility Overview
In the past 24 hours, ORDER's price hit a low of $0.051 and a high of $0.0735, currently quoted at $0.0686, with a price swing of 44.1%, presenting a pattern of initial surge followed by a pullback. The 24-hour trading volume was about $45.27 million, down 18.9% from the previous day, but with a significant improvement in overall liquidity.
Brief Analysis of Fluctuation Causes
- Network Upgrade Announcement: On April 7, Orderly Network announced another upgrade. Foxify introduced the "FUNDED" product into PerpTools (a perp DEX powered by Orderly), covering 100+ trading pairs, attracting the DEXTools user ecosystem of 20 million, and boosting perp liquidity.
- Funding Rate Arbitrage Opportunity: On April 7, the long-short funding rate spread for $ORDER reached 2.13% (annualized 776.54%), attracting cross-exchange arbitrage such as Bybit long/Bitget short, which drove trading activity.
- Continued Trading Volume Surge: Recently, the 24-hour trading volume had surged by 2,192% to $86.2 million, with the influx of liquidity amplifying volatility.
Market Views and Outlook
The mainstream sentiment in the community is positive, seeing the upgrade as a key catalyst for perp DEX adoption, with expectations that more integrations will push up TVL. High funding rates may continue to attract arbitrage, but analysts caution about volatility risks and warn of a possible pullback to the $0.06 support level.
Note: This analysis is automatically generated by AI based on publicly available data and on-chain monitoring, and is for informational purposes only.Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
RBA set to hike interest rate to 4.60% in September as inflation remains elevated
AstraZeneca invests $2 billion in Summit, optimistic about Akeso's Ivose
This 18.6% premium subscription is not only a substantial endorsement, but both parties will also deeply collaborate on the joint development of combination therapies such as ADCs. The core of this deal is Akeso's Ivonescimab—the world’s first PD-1/VEGF bispecific antibody, and so far the only drug to have surpassed "K-drug" in head-to-head trials on both PFS and OS endpoints. The median OS reached 30.8 months, compared to 22.6 months for "K-drug", representing a 27% reduction in risk of death.
AMD (AMD.US) Surpasses $1 Trillion Market Cap and Begins Competing for "Computing Power Definition Rights"! Officially Announces $8.2 Billion Acquisition of Fei-Fei Li's World Labs
AMD has agreed to acquire World Labs for $8.2 billion, thereby gaining access to the artificial intelligence startup founded by industry pioneer and researcher Fei-Fei Li. This acquisition is expected to help AMD plan its future hardware launches by bringing in a team of top researchers and their models, as well as deep insights into trends in the field of artificial intelligence.
Crypto prices
More
